从反义中找到合理！
Making safe sense of an anti-sense!
机构信息
Blizard Institute, Centre for Immunobiology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, St Mary's Hospital London, UK.
出版信息
Cell Rep Med. 2022 Jan 18;3(1):100503. doi: 10.1016/j.xcrm.2021.100503.
Abstract
Bepiroversen has been developed and trialed for the cure of HBV. Yuen et al. report on the safety and antiviral efficacy of this agent. We "spotlight" key findings of this study and its impact for future clinical trial design.
摘要
贝匹罗versen 已被开发并用于治疗 HBV。Yuen 等人报告了该药物的安全性和抗病毒疗效。我们“聚焦”了这项研究的关键发现及其对未来临床试验设计的影响。
相似文献
1
Making safe sense of an anti-sense!从反义中找到合理！
Cell Rep Med. 2022 Jan 18;3(1):100503. doi: 10.1016/j.xcrm.2021.100503.
2
Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?慢性乙型肝炎即将到来的药理学进展：我们能看到治愈的曙光吗？
BMC Gastroenterol. 2017 Dec 21;17(1):168. doi: 10.1186/s12876-017-0726-2.
3
Comparative evaluation of L-Fd4C and related nucleoside analogs as promising antiviral agents.L-Fd4C及相关核苷类似物作为有前景的抗病毒药物的比较评价。
Curr Med Chem. 2002 May;9(9):899-912. doi: 10.2174/0929867024606696.
4
Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.REP 2139-Ca 和聚乙二醇干扰素治疗慢性乙型肝炎/丁型肝炎病毒合并感染后对乙型肝炎病毒和丁型肝炎病毒感染的持续控制。
Hepatol Commun. 2020 Nov 13;5(2):189-202. doi: 10.1002/hep4.1633. eCollection 2021 Feb.
5
Discovery and optimizing polycyclic pyridone compounds as anti-HBV agents.发现并优化多环吡啶酮类化合物作为抗乙肝病毒药物。
Expert Opin Ther Pat. 2020 Sep;30(9):715-721. doi: 10.1080/13543776.2020.1801641. Epub 2020 Aug 9.
6
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.在初治慢性乙型肝炎病毒感染患者中，韦比科韦与恩替卡韦联合使用的安全性和有效性。
J Hepatol. 2022 Nov;77(5):1265-1275. doi: 10.1016/j.jhep.2022.05.027. Epub 2022 Jun 11.
7
Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.在常规临床实践中，接受直接作用抗病毒治疗的丙型肝炎患者中乙型肝炎病毒再激活。
J Clin Virol. 2017 Aug;93:66-70. doi: 10.1016/j.jcv.2017.05.021. Epub 2017 Jun 3.
8
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.48周的REP 2139或REP 2165、替诺福韦酯和聚乙二醇化干扰素α-2a在初治慢性乙型肝炎病毒感染患者中的安全性和疗效
Gastroenterology. 2020 Jun;158(8):2180-2194. doi: 10.1053/j.gastro.2020.02.058. Epub 2020 Mar 6.
9
Meeting report: 27th International conference on antiviral research, in Raleigh, NC, USA.会议报告：第27届美国北卡罗来纳州罗利市国际抗病毒研究会议
Antiviral Res. 2014 Nov;111:143-53. doi: 10.1016/j.antiviral.2014.08.009. Epub 2014 Sep 16.
10
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.REP 2139 和聚乙二醇干扰素 α-2a 治疗初治慢性乙型肝炎病毒和丁型肝炎病毒合并感染患者的安全性和疗效（REP 301 和 REP 301-LTF）：一项非随机、开放标签、2 期临床试验。
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):877-889. doi: 10.1016/S2468-1253(17)30288-1. Epub 2017 Sep 28.
本文引用的文献
1
Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.在慢性乙型肝炎患者中，反义寡核苷酸药物 bepirovirsen 的安全性、耐受性和抗病毒活性：一项 2 期随机对照试验。
Nat Med. 2021 Oct;27(10):1725-1734. doi: 10.1038/s41591-021-01513-4. Epub 2021 Oct 12.
2
Paradoxical HBsAg and anti-HBs coexistence among Chronic HBV Infections: Causes and Consequences.HBsAg 和抗-HBs 共存于慢性 HBV 感染中：原因和后果。
Int J Biol Sci. 2021 Mar 11;17(4):1125-1137. doi: 10.7150/ijbs.55724. eCollection 2021.
3
Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection.乙型肝炎表面抗原对慢性乙型肝炎病毒感染患者病毒特异性和整体 T 细胞的影响。
Gastroenterology. 2020 Aug;159(2):652-664. doi: 10.1053/j.gastro.2020.04.019. Epub 2020 Apr 14.
4
Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad.血清丙氨酸氨基转移酶 flares 在慢性乙型肝炎感染：好的和坏的。
Lancet Gastroenterol Hepatol. 2020 Apr;5(4):406-417. doi: 10.1016/S2468-1253(19)30344-9. Epub 2020 Feb 10.
5
Emerging tools in the changing landscape of chronic hepatitis B management.慢性乙型肝炎管理变化格局中的新兴工具。
Expert Rev Anti Infect Ther. 2019 Dec;17(12):943-955. doi: 10.1080/14787210.2019.1694906. Epub 2019 Nov 27.
6
Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.未经治疗的慢性乙型肝炎感染患者中，严重血清丙氨酸氨基转移酶 flares 与乙型肝炎 e 抗原血清学转换和 HBV DNA 下降之间的关联。
Clin Gastroenterol Hepatol. 2019 Nov;17(12):2541-2551.e2. doi: 10.1016/j.cgh.2019.02.005. Epub 2019 Feb 8.
7
Fine needle aspirates comprehensively sample intrahepatic immunity.细针穿刺全面取样肝内免疫。
Gut. 2019 Aug;68(8):1493-1503. doi: 10.1136/gutjnl-2018-317071. Epub 2018 Nov 28.
8
Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo.干扰素α在体内诱导自然杀伤细胞对乙肝病毒载量抑制反应的持续变化。
PLoS Pathog. 2016 Aug 3;12(8):e1005788. doi: 10.1371/journal.ppat.1005788. eCollection 2016 Aug.
9
In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides.反义寡核苷酸体内降低乙型肝炎病毒抗原血症和病毒血症。
J Hepatol. 2016 Apr;64(4):781-9. doi: 10.1016/j.jhep.2015.11.032. Epub 2015 Nov 30.
10
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?慢性乙型肝炎：聚乙二醇干扰素还是核苷（酸）类似物？
Liver Int. 2011 Jan;31 Suppl 1:78-84. doi: 10.1111/j.1478-3231.2010.02384.x.
Zotero 插件